Please login to the form below
Tecfidra
This page shows the latest Tecfidra news and features for those working in and with pharma, biotech and healthcare.
Tecfidera successor’s side-effect profile boosts Biogen
8%, 15.4% and 14.6% for Vumerity 40.6%, 22.3% and 20.7% for Tecfidra).
Latest news
-
Biogen grows in Q2, but Spinraza performance a concern
Company banking on pipeline readouts and Tecfidra defence. Biogen has exceeded expectations in overall Q2 revenues from its multiple sclerosis franchise and biosimilars, but worse than expected performance from its key
-
Biogen trumpets safety data for Tecfidera follow-up
Much riding on blockbuster's successor
-
Spinraza keeps Biogen afloat as Tecfidra stalls
While this pipeline will take time to mature, and Tecfidra facing a patent challenge in the US, the strong performance of Spinraza and its biosimilar franchise helped Biogen keep moving forward. ... Biogen and partner Alkermes are also awaiting an FDA
-
Biogen files Tecfidera follow-up in the US
Improved GI tolerability is major selling point
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck enters agreement with Hanmi for investigational NASH drug
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Novo Nordisk growth takes a hit with China deal
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
